Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis

Manalo, Iviensan F.; Gilbert, Kathleen E.; Wu, Jashin J.

doi:10.1016/j.jaad.2015.07.023

Cited by 6 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If HBV or HCV infection is diagnosed with concomitant PsO, the National Psoriasis Foundation (NPF) recommends consultation between a dermatologist and hepatologist before and throughout immunosuppressive treatment to define the stage of disease and extent of liver damage [43][44][45]. Active HBV infection must be treated prior to administration of immunosuppressive therapies, and patients should be monitored every 3 months for HBV DNA load and transaminase levels in case of reactivation [43,46].…”

Section: Hbv and Hcvmentioning

confidence: 99%

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Merola

Feldman

et al. 2020

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. PsO is associated with a high prevalence of comorbidities, including other autoimmune diseases and malignancies. Furthermore, special populations, such as pregnant, pediatric, and elderly patients, and those with erythrodermic PsO, are challenging to treat and require tightly monitored disease and treatment management. Because certain populations have demographic or clinical characteristics that can affect the presentation of PsO and complicate treatment responses, these patient populations are largely excluded from clinical trials; therefore, most clinical evidence for the treatment of these patients is derived from case reports and series. Secukinumab, a fully human monoclonal interleukin-17A antibody, has been shown in several clinical trials to be effective and safe for the treatment of PsO; however, these studies offer only limited data on the use of secukinumab in patients with chronic illnesses or in special populations. This review explores the use of secukinumab for PsO in special populations, including pregnant women, children, elderly people, patients with erythrodermic PsO, and those with chronic illnesses, including latent tuberculosis, hepatitis B and C, HIV, multiple sclerosis, and malignancies.

show abstract

Section: Hbv and Hcvmentioning

confidence: 99%

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Merola

Feldman

et al. 2020

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Taiwan, because of the relatively high prevalence of HBV and HCV infection (13), all patients treated with secukinumab underwent pretreatment screening for HBV and HCV markers. The serological findings for positive HBV infection was subdivided into 3 categories according to the 2014 National Psoriasis Foundation recommendations: (i) chronic HBV infection (HBsAg-positive), (ii) resolved HBV infection (HBsAg-negative, HBsAb-positive, and HBcAb-positive), and (iii) occult HBV infection (HBsAg-negative, HBsAb-negative, and HBcAb-positive) (14). HCV infection was defined by the seropositivity of anti-HCV antibody.…”

Section: Study Populationmentioning

confidence: 99%

“…Patients without viral load data at baseline or at a minimum of 2 different time-points were excluded. As recommended by various guideline (14,15), patients with positive HBV-or HCV-carrier status are suggested to receive antiviral prophylaxis. However, based on the Bureau of National Health Insurance (BNHI) reimbursement policy in Taiwan, prophylactic use of antiviral therapy for HBV carriers is restricted to patients with cancer undergoing chemotherapy, or organ-transplant patients undergoing immunosuppressants.…”

Section: Study Populationmentioning

confidence: 99%

Safety Proﬁle of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study

Chiu¹,

Hui²,

Huang³

et al. 2018

Acta Derm Venerol

View full text Add to dashboard Cite

SIGNIFICANCEThis study showed that biologic agents alter the competence of the host immune-surveillance system to combat hepatitis virus infections and hepatitis B virus (HBV) or hepatitis C virus (HCV). Reactivation can occur in patients with psoriasis with concurrent HBV or HCV treated with secukinumab, an anti-interleukin 17 agent. The risk of virus reactivation varied in patients with psoriasis with different virological profiles. It is advisable to monitor the viral load/ serum transaminase level and consider antiviral prophylaxis for all hepatitis B surface antigen-positive patients with psoriasis who are being treated with secukinumab.

show abstract

“…In contrast, the psoriasis literature has predominantly demonstrated a higher reactivation rate in patients with chronic HBV Letters to the Editor e549 infection. 6,7 In psoriasis patients with resolved HBV infection, the level of risk is not as evident. Sanz-Bueno et al estimated a maximum risk of HBV reactivation of 2.7 cases per 100 psoriasis patients with resolved HBV receiving treatment with a biologic.…”

Section: Adalimumab Use In Patients With Psoriasis and Hepatitis B: Amentioning

confidence: 99%

Adalimumab use in patients with psoriasis and hepatitis B: a case series

Amin

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis

Cited by 6 publications

References 7 publications

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Safety Proﬁle of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study

Adalimumab use in patients with psoriasis and hepatitis B: a case series

Contact Info

Product

Resources

About